Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Willemijn J. Jansen, Olin Janssen, Betty M. Tijms, et al.
JAMA Neurology (2022) Vol. 79, Iss. 3, pp. 228-228
Open Access | Times Cited: 161

Showing 1-25 of 161 citing articles:

Hallmarks of neurodegenerative diseases
David M. Wilson, Mark Cookson, Ludo Van Den Bosch, et al.
Cell (2023) Vol. 186, Iss. 4, pp. 693-714
Open Access | Times Cited: 769
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 480
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Nicholas J. Ashton, Wagner S. Brum, Guglielmo Di Molfetta, et al.
JAMA Neurology (2024) Vol. 81, Iss. 3, pp. 255-255
Open Access | Times Cited: 240
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 211
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
Niklas Mattsson, Gemma Salvadó, Nicholas J. Ashton, et al.
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 360-360
Open Access | Times Cited: 156
Aducanumab: Appropriate Use Recommendations Update
Jeffrey L. Cummings, Gil D. Rabinovici, Alireza Atri, et al.
The Journal of Prevention of Alzheimer s Disease (2022)
Open Access | Times Cited: 136
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 116
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Hugh Pemberton, Lyduine E. Collij, Fiona Heeman, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 10, pp. 3508-3528
Open Access | Times Cited: 106
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Wagner S. Brum, Nicholas Cullen, Shorena Janelidze, et al.
Nature Aging (2023) Vol. 3, Iss. 9, pp. 1079-1090
Open Access | Times Cited: 106
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
Marianne Chapleau, Leonardo Iaccarino, David N. Soleimani‐Meigooni, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. Supplement 1, pp. 13S-19S
Open Access | Times Cited: 102
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 69
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 51
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Leonidas Chouliaras, John T. O’Brien
Molecular Psychiatry (2023) Vol. 28, Iss. 10, pp. 4084-4097
Open Access | Times Cited: 50
Multifaceted roles of APOE in Alzheimer disease
Rosemary J. Jackson, Bradley T. Hyman, Alberto Serrano‐Pozo
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 457-474
Closed Access | Times Cited: 27
APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology
Augustine Chemparathy, Yann Le Guen, Sunny Chen, et al.
Neuron (2024) Vol. 112, Iss. 7, pp. 1110-1116.e5
Open Access | Times Cited: 19
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays
Daniel Figdore, Michael Griswold, Joshua A. Bornhorst, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6506-6516
Open Access | Times Cited: 15
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 6
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Przemysław R. Kac, Fernándo González‐Ortiz, Joel Simrén, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
Francisco Martínez‐Dubarbie, Armando Ruiz, Sara López‐García, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Hanna Cho, Nidhi S. Mundada, Liana G. Apostolova, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. S9
Open Access | Times Cited: 32
Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
Nicholas J. Ashton, Wagner S. Brum, Guglielmo Di Molfetta, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 25
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Lan Zhang, Yiyuan Xia, Yuran Gui
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 23
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Poul Flemming Høilund‐Carlsen, Abass Alavi, Rudolph J. Castellani, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3892-3892
Open Access | Times Cited: 14
New precision medicine avenues to the prevention of Alzheimer’s disease from insights into the structure and function of γ-secretases
Bart De Strooper, Eric Karran
The EMBO Journal (2024) Vol. 43, Iss. 6, pp. 887-903
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top